Repligen CorporationRR

Repligen Corporation

139.34USDR
−5.54−3.82%
At close at Mar 20, 23:54 GMT
USD
No trades
See on Supercharts

RGEN fundamentals

Key facts

Market capitalization‪7.82 B‬USD
Basic EPS (TTM)−0.45USD
Founded1981
Employees (FY)‪1.78 K‬
CEOOlivier Dominique Loeillot
About

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Ownership
‪‪56.03 M‬‬
Free Float shares
‪‪52.91 M‬‬ (94.43%)
Closely held shares
‪‪3.12 M‬‬ (5.57%)
Free Float shares
‪‪52.91 M‬‬ (94.43%)
Closely held shares
‪‪3.12 M‬‬ (5.57%)
Capital structure
Market cap
‪‪7.82 B‬‬
Debt
‪‪686.25 M‬‬
Cash & equivalents
‪‪757.36 M‬‬
Enterprise value
‪‪7.75 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪7.82 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
12.80x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
12.80x
Valuation ratios
‪0.00‬
‪4.50‬
‪9.00‬
‪13.50‬
‪18.00‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪200.00‬
‪400.00‬
‪600.00‬
‪800.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−21%‬
‪−14%‬
‪−7%‬
‪0%‬
‪7%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−60.00 M‬‬
‪0.00‬
‪‪60.00 M‬‬
‪‪120.00 M‬‬
‪‪180.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−60.00 M‬‬
‪0.00‬
‪‪60.00 M‬‬
‪‪120.00 M‬‬
‪‪180.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−60.00 M‬‬
‪0.00‬
‪‪60.00 M‬‬
‪‪120.00 M‬‬
‪‪180.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Filtration
Chromatography
Proteins
Process Analytics
Other
Royalty and Other
By country
Period: 2024
North America
Europe
APAC/Other

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪45.00 M‬‬
‪‪90.00 M‬‬
‪‪135.00 M‬‬
‪‪180.00 M‬‬
Actual
Estimate
Earnings
Next:Apr 30, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪0.11‬
‪0.22‬
‪0.33‬
‪0.44‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

RGEN does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪210.00 M‬‬
‪‪420.00 M‬‬
‪‪630.00 M‬‬
‪‪840.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪500.00 M‬‬
‪‪1.00 B‬‬
‪‪1.50 B‬‬
‪‪2.00 B‬‬
Assets
Liabilities